Belgian heart patients tracked on new cholesterol drug

NCT ID NCT05726838

Summary

This study is observing 600 Belgian patients with heart disease who are taking the cholesterol-lowering injection inclisiran along with their standard medications. Researchers are tracking how well the drug lowers 'bad' cholesterol (LDL-C) in real-world doctor's offices, not a controlled trial. The goal is to understand how effective and safe the treatment is when used in everyday medical practice.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Turnhout, Antwerpen, 2300, Belgium

  • Novartis Investigative Site

    Genk, Limburg, 3600, Belgium

  • Novartis Investigative Site

    Yvoir, Namur, 5530, Belgium

  • Novartis Investigative Site

    Leuven, Vlaams Brabant, 3000, Belgium

  • Novartis Investigative Site

    Kortrijk, West-Vlaanderen, 8500, Belgium

  • Novartis Investigative Site

    Aalst, 9300, Belgium

  • Novartis Investigative Site

    Anderlecht, 1070, Belgium

  • Novartis Investigative Site

    Brasschaat, 2930, Belgium

  • Novartis Investigative Site

    Brussels, 1020, Belgium

  • Novartis Investigative Site

    Edegem, 2650, Belgium

  • Novartis Investigative Site

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    Haine-Saint-Paul, 7100, Belgium

  • Novartis Investigative Site

    Huy, 4500, Belgium

  • Novartis Investigative Site

    Liège, 4000, Belgium

  • Novartis Investigative Site

    Mechelen, 2800, Belgium

Conditions

Explore the condition pages connected to this study.